LAVA Therapeutics NV (LVTX) Stock News

USA - Nasdaq - NASDAQ:LVTX - NL0015000AG6 - Common Stock

1.74 USD

-0.07 (-3.87%)

Last: 11/20/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LVTX Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: XOMA Royalty Corporation - Mentions: XOMA

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

25 days ago - By: LAVA Therapeutics N.V.

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq

a month ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

2 months ago - By: Ademi LLP

Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

2 months ago - By: Stocktwits - Mentions: XOMA

News Image

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

a year ago - By: BusinessInsider

News Image

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

a year ago - By: InvestorPlace

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

2 months ago - By: Stocktwits - Mentions: XOMA

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

2 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V. - Mentions: XOMA

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

2 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics - Mentions: XOMA

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

2 years ago - By: BusinessInsider

News Image

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024

2 months ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

3 months ago - By: Benzinga - Mentions: CSBR CAPR TCRT

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

4 months ago - By: LAVA Therapeutics N.V.

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Halper Sadeh LLP - Mentions: SCS

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

4 months ago - By: Benzinga - Mentions: INSP IP NVO XYZ

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

4 months ago - By: Brodsky & Smith LLC - Mentions: HLVX SCS RKDA XOMA ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

4 months ago - By: Halper Sadeh LLC

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

4 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V. - Mentions: XOMA

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

7 months ago - By: LAVA Therapeutics N.V.

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

8 months ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

9 months ago - By: LAVA Therapeutics N.V.

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

a year ago - By: LAVA Therapeutics N.V.

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

a year ago - By: LAVA Therapeutics N.V.

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: LAVA Therapeutics N.V.

LAVA Reports Second Quarter 2024 Financial Results and Business Update

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

1 years ago - By: LAVA Therapeutics N.V.

LAVA Announces Annual Meeting of Shareholders

1 years ago - By: LAVA Therapeutics N.V.

LAVA Announces Annual Meeting of Shareholders

2 years ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

2 years ago - By: InvestorPlace

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024